LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

COVID‐19 mortality in patients on anticoagulants and antiplatelet agents

Photo by nci from unsplash

Abstract Coagulopathy (Tang, et al 2020) and a prothrombotic diathesis with high D‐dimer and fibrinogen levels (Al‐Samkari, et al 2020) are associated with coronavirus disease 2019 (COVID‐19) caused by severe… Click to show full abstract

Abstract Coagulopathy (Tang, et al 2020) and a prothrombotic diathesis with high D‐dimer and fibrinogen levels (Al‐Samkari, et al 2020) are associated with coronavirus disease 2019 (COVID‐19) caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Extensive thrombosis in small vessels and the microvasculature in lungs and extrapulmonary organs has been confirmed histologically (Zhang et al 2020). Early studies showed that the venous thromboembolism (VTE) incidence in hospitalised COVID‐19 patients can be as high as 25% (Songping, et al 2020), and more recent studies have indicated this can be expanded to other macrovascular thrombotic complications, such as a higher than expected prevalence of pulmonary emboli in patients with COVID‐19 (Klok, et al 2020, Stoneham, et al).

Keywords: patients anticoagulants; covid mortality; anticoagulants antiplatelet; antiplatelet agents; mortality patients

Journal Title: British Journal of Haematology
Year Published: 2020

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.